Mindbloom

What it is

Mindbloom offers at-home ketamine-assisted therapy for people with anxiety, depression, and PTSD. The company mails you ketamine, either as subcutaneous injectables or sublingual tablets, and you administer treatment at home under remote guidance from a licensed clinician and a trained guide. The entire experience is telehealth-supported. Mindbloom is not a DIY approach: you work with a psychiatric clinician who prescribes and monitors your treatment, a guide who coaches you before and after sessions, and a live support team available via SMS, email, and chat. The ketamine is compounded by pharmacies under federal law (Section 503A of the Food, Drug, and Cosmetic Act), which means the FDA has not evaluated the specific formulations for safety and efficacy in treating anxiety, depression, or PTSD, though the company says the therapeutic use is supported by scientific literature. Ketamine itself is a Schedule III controlled substance and is FDA-approved as an injectable solution for surgical anesthesia, but not for mental health conditions in the forms or doses Mindbloom prescribes.

How the program works

The process starts with an eligibility quiz on the Mindbloom site, which leads to a virtual consultation with a psychiatric clinician. You must be 18 or older, live in or be able to visit one of the states where Mindbloom operates, and have a valid shipping address in an available state. The clinician will take your medical history, review current medications, and assess whether ketamine is appropriate for you. If they determine it is, they will prescribe a starting dose and help you choose between Mindbloom Injectables (subcutaneous) or Mindbloom Tablets (sublingual). The company states that 81% of clients prefer injectables, which may indicate that one form is more commonly chosen or more effective for most users, though the site does not elaborate on why.

Your treatment unfolds in sessions, each lasting 45 minutes to 1 hour. You take the dose at home and then enter the therapeutic experience, usually described by clients as gentle and introspective, with sensations of weightlessness and a dreamlike state. A critical safety requirement: a peer treatment monitor must be physically present with you during every session. After each session, you share your experience with your care team, and your clinician may adjust your dosage based on your response. The company says some clients see improvements right after their first session, while others need a few more to feel results, but that 89% of clients report improvement after 4 sessions. Beyond symptom relief, Mindbloom frames ketamine as working through neuroplasticity, rewiring neural pathways, which the company says leads to lasting emotional healing and lifestyle changes, not just temporary symptom suppression.

Your guide offers 1-on-1 coaching to help you prepare and integrate experiences. The company also hosts Group Integration Circles where clients can connect with others going through the program. This support structure is part of the differentiator Mindbloom emphasizes; the messaging is that ketamine treatment alone is not enough, and the coaching and community component is essential to outcomes.

Costs, insurance, and clinical findings

Mindbloom does not directly accept insurance for ketamine therapy. However, you can request a superbill after your initial consultation, an itemized receipt that includes billing codes so you can submit it to your insurance and attempt out-of-network reimbursement. The company says "you may be eligible to reimburse over 50% of your program cost through insurance," which suggests the starting cost is meaningful and that partial coverage is plausible for many plans, though individual plans vary widely. If you have an HSA (Health Savings Account) or FSA (Flexible Spending Account), those funds may be eligible to pay for Mindbloom services, though the company advises confirming with your plan. The site does not publish upfront pricing; you learn cost during the consultation or checkout process.

The company has published peer-reviewed research backing its effectiveness. A 2022 study in the Journal of Affective Disorders examined real-world outcomes from a large, prospective open-label trial of at-home sublingual ketamine telehealth. The headline findings are: 89% of clients reported improvement in depression and anxiety symptoms; 95% reported no side effects; 84% of clients who experienced significant improvements maintained their progress or recovered with a second round of treatment. The FDA has not run head-to-head trials comparing ketamine to FDA-approved psychiatric medications, and the FDA has not approved compounded ketamine for mental health conditions. The company is transparent that some clients report more success with ketamine than FDA-approved therapies, but notes "these outcomes may not be typical." The research cited comes from Mindbloom's own client population, not independent clinical trials, though it was published in a peer-reviewed journal.

Strict eligibility and safety limits

The service has a long list of contraindications. You cannot use ketamine if you are allergic to it, have symptoms of psychosis or mania, have uncontrolled high blood pressure, serious heart problems, severe breathing problems, history of elevated eye or brain pressure, history of hyperthyroidism, other serious medical illness, or if you are pregnant, nursing, or trying to become pregnant. Ketamine has been found to cause moderate psychological dependency in some users, and while most clients report no side effects, the possible serious effects include sedation, dissociation, psychiatric events, worsening of existing mental illness, increased blood pressure or heart rate, respiratory depression, urinary symptoms, confusion, nausea, blurred vision, and slurred speech. The FDA has specifically advised that at-home administration of compounded ketamine carries additional risks because a healthcare provider is not available onsite to monitor for adverse outcomes. To minimize these risks, Mindbloom requires you not to drive or operate machinery until you have had a full night of sleep after treatment, to skip benzodiazepines and stimulants for 24 hours before treatment, to avoid alcohol and food/liquid in specific timeframes before treatment, and to continue blood pressure medication if prescribed.

Who this fits

Mindbloom fits someone with treatment-resistant anxiety, depression, or PTSD who has already tried conventional medications and therapy without adequate improvement, or someone who wants to explore a different mechanism than traditional antidepressants. It suits someone who can receive ketamine in a safe home environment with reliable support, can commit to ongoing telehealth appointments and integration work, and is willing to navigate out-of-network insurance reimbursement (or pay out of pocket). It is appropriate for someone in a state where Mindbloom operates who wants a faster treatment arc; the company's framing is that results can appear within weeks rather than the months conventional therapy might take. It works for people with health insurance that might partially cover out-of-network mental health treatment, or for those with HSA/FSA funds.

It does not fit someone in a state without Mindbloom availability, someone with contraindicated medical conditions or psychiatric histories, someone without a safe home environment or without a trusted monitor who can be present during sessions, someone not comfortable with a controlled substance, or someone who prefers in-person clinical contact over telehealth. It is not appropriate for someone in crisis or with acute suicidality; the site focuses on chronic conditions. It is not a substitute for emergency psychiatric care. And it is not an option for anyone under 18, even with parental consent.